BeiGene, Ltd. Share Price

Equities

BGNE

US07725L1026

Biotechnology & Medical Research

Market Closed - Nasdaq 01:30:00 22/06/2024 am IST 5-day change 1st Jan Change
156.1 USD +0.37% Intraday chart for BeiGene, Ltd. -3.98% -13.45%
Sales 2024 * 3.24B 271B Sales 2025 * 4.02B 336B Capitalization 16.45B 1,374B
Net income 2024 * -859M -71.76B Net income 2025 * -346M -28.9B EV / Sales 2024 * 4.58 x
Net cash position 2024 * 1.6B 134B Net cash position 2025 * 1.01B 84.02B EV / Sales 2025 * 3.84 x
P/E ratio 2024 *
-17.3 x
P/E ratio 2025 *
-43.1 x
Employees 10,000
Yield 2024 *
-
Yield 2025 *
-
Free-Float 98.21%
More Fundamentals * Assessed data
Dynamic Chart
Beigene Insider Sold Shares Worth $368,162, According to a Recent SEC Filing MT
BeiGene, Ltd.(SHSE:688235) added to Shanghai Stock Exchange Health Care Sector Index CI
BeiGene Says New Phase 3 Brukinsa Data Show 'Promising' Efficacy in Leukemia, Lymphoma MT
BeiGene to Present New Data from SEQUOIA Study Evaluating BRUKINSA® plus Venetoclax in High-Risk First-Line CLL/SLL at EHA2024 CI
Beijing Gene Announces Dose the First Five Patients in Its First-In-Human Phase 1 Trial to Evaluate BG-68501 CI
Beigene Issues Shares Under Incentive Schemes MT
Transcript : BeiGene, Ltd. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-11-2024 01:20 PM
Zymeworks Says China's Health Regulator Accepts Biologics License Application for Cancer Therapy MT
BriaCell Announces Clinical Supply Agreement with BeiGene for Bria-OTS First in Human Study MT
BriaCell Therapeutics, BeiGene Partner to Test Combination of Companies' Cancer Treatments MT
BriaCell Therapeutics Corp. Announces Clinical Supply Agreement with BeiGene, Ltd. for Bria-OTS First in Human Study CI
BeiGene Says Studies Highlight Effectiveness, Safety of Lymphoma Drug Brukinsa MT
BeiGene, Ltd. Announces New Analyses for BRUKINSA® (zanubrutinib) At ASCO Underscore Differentiated Clinical Profile for Treatment of CLL and SLL CI
Glenmark Pharma Arm to Market Two Beigene Cancer Drugs in India MT
Glenmark Specialty S.A. Announces an Exclusive Marketing and Distribution Agreement with BeiGene CI
More news
1 day+0.37%
1 week-3.98%
Current month+4.88%
1 month-6.74%
3 months-4.64%
6 months-11.85%
Current year-13.45%
More quotes
1 week
150.88
Extreme 150.88
165.30
1 month
144.66
Extreme 144.66
169.17
Current year
126.97
Extreme 126.9681
184.80
1 year
126.97
Extreme 126.9681
225.23
3 years
118.18
Extreme 118.18
426.56
5 years
114.41
Extreme 114.41
426.56
10 years
22.51
Extreme 22.51
426.56
More quotes
Date Price Change Volume
21/24/21 156.1 +0.37% 217,941
20/24/20 155.5 +0.54% 129,240
18/24/18 154.7 -2.94% 170,761
17/24/17 159.4 -1.97% 97,166
14/24/14 162.6 -2.28% 174,057

Delayed Quote Nasdaq, June 22, 2024 at 01:30 am IST

More quotes
BeiGene, Ltd. is a global biotechnology company engaged in discovering and developing oncology treatments for cancer patients worldwide. The Company has discovered and developed three approved medicines, including BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase for the treatment of various blood cancers; TEVIMBRA (tislelizumab), an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and pamiparib, a selective small molecule inhibitor of poly ADP-ribose polymerase 1 (PARP1) and PARP2. The Company has obtained approvals to market BRUKINSA in the United States, the People's Republic of China (China or the PRC), the European Union, the United Kingdom, Canada, Australia, and additional international markets; tislelizumab in the European Union and China; and pamiparib in China. It also focuses on commercializing cancer medicines, such as XGEVA, BLINCYTO, KYPROLIS, and others in China under an exclusive license from Amgen Inc.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
21
Last Close Price
156.1 USD
Average target price
267 USD
Spread / Average Target
+71.04%
Consensus